Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E7 TCR T Cells for Vulvar HSIL
NCT03937791Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Oct 2019
- Primary completion
- Jun 2020
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of KITE-439 in vulvar high-grade squamous intraepithelial lesion, sponsored by National Cancer Institute. Primary endpoint: Fraction of Participants With Vulvar High-Grade Squamous Intraepithelial Lesions (HSIL) Who Experience a Complete Response at 3 months. Started Oct 2019; status: terminated.
02
Drugs
KITE-439
03
Conditions
vulvar high-grade squamous intraepithelial lesion
Beyond the preview
Go deeper on NCT03937791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03937791.